The VUB is an Urban Engaged University that is firmly committed to the fight against cancer through scientific research. Scientists from various fields – medicine, bioengineering, pharmacy, physiotherapy, psychology – work together on an interdisciplinary basis.
Start-up Esobiotec and the VUB aim to develop cost-effective and off-the-shelf therapeutics that are inspired on this promising cancer immunotherapy. To achieve this goal, technologies developed at the VUB will be leveraged to manipulate the cell directly in the blood, without having to isolate them first from the body. This disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment.
Esobiote was founded by Jean-Pierre Latere and two VUB researchers and their teams: Nick Devoogdt from the Medical Imaging department (MIMA) and Karine Breckpot from the Laboratory for Molecular and Cellular Therapy (LMCT).